EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity

David M Williams, Matthew Staff, Stephen C Bain, Thinzar Min

Endocrinology · 2022

DOI: 10.17925/ee.2022.18.1.43 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology, 2022. Verfasst von David M Williams und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This article is published under the Creative Commons Attribution Non-commercial License..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™ - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy.

Schlagwörter

Stichwörter der Autor:innen

Glucagon-like peptide-1 (GLP-1) receptor analoguediabetes mellitusliraglutideobesityoverweightsemaglutidetype 2 diabetesweight lossweight management

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK.
  • Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, UK.
  • Department of Diabetes and Endocrinology, Neath Port Talbot Hospital, Swansea Bay University Health Board, Swansea, UK.

Förderung

  • This article is published under the Creative Commons Attribution Non-commercial License.

Zitieren

APA

Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022). Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. Endocrinology. https://doi.org/10.17925/ee.2022.18.1.43

Vancouver

Williams DM, Staff M, Bain SC, Min T. Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. Endocrinology. 2022. doi:10.17925/ee.2022.18.1.43

BibTeX
@article{Williams2022,
  author = {Williams, David M and Staff, Matthew and Bain, Stephen C and Min, Thinzar},
  title = {Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity},
  journal = {Endocrinology},
  year = {2022},
  doi = {10.17925/ee.2022.18.1.43}
}
Kostenlos starten →